Insmed Incorporated

INSM

US4576693075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 18/02/2026 am IST			5-day change	1st Jan Change
150.52 ^USD	+1.19%		+1.33%	-13.51%

12/02	Insmed Insider Sold Shares Worth $1,979,764, According to a Recent SEC Filing	MT
28/01	Barclays Initiates Coverage on Insmed With Overweight Rating, $231 Price Target	MT

Insmed Incorporated(NasdaqGS:INSM) dropped from Russell 2000 Growth Index

Published on 06/30/2025 at 07:55 am IST

S&P Capital IQ

INSMED INCORPORATED

+1.19%

Insmed Incorporated(NasdaqGS:INSM) dropped from Russell 2000 Growth Index

Latest news about Insmed Incorporated

12/02	Insmed Insider Sold Shares Worth $1,979,764, According to a Recent SEC Filing	MT
28/01	Barclays Initiates Coverage on Insmed With Overweight Rating, $231 Price Target	MT
23/01	Roth Capital Initiates Coverage on Insmed With Buy Rating, $212 Price Target	MT
21/01	RBC Raises Price Target on Insmed to $200 From $197, Keeps Outperform Rating	MT
14/01	Insmed Insider Sold Shares Worth $351,341, According to a Recent SEC Filing	MT
14/01	Insmed Insider Sold Shares Worth $3,247,349, According to a Recent SEC Filing	MT
13/01	Insmed Incorporated Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 03:00 PM
09/01	Insmed Incorporated Provides Revenue Guidance for the Full Year 2025	CI
09/01	Sector Update: Health Care Stocks Rise Pre-Bell Friday	MT
09/01	Sector Update: Health Care	MT
09/01	Insmed Reports Higher Preliminary 2025 Revenue; Shares Up Pre-Bell	MT
09/01	Insmed Insider Sold Shares Worth $746,711, According to a Recent SEC Filing	MT
09/01	Insmed Insider Sold Shares Worth $549,494, According to a Recent SEC Filing	MT
08/01	RBC Lifts Price Target on Insmed to $197 From $195, Keeps Outperform Rating	MT
07/01	Insmed Insider Sold Shares Worth $15,293,422, According to a Recent SEC Filing	MT

Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Employees

1,271

Sector

Biotechnology & Medical Research

Calendar

19/02 - Q4 2025 Earnings Release

More about the company